Signal brief

ASTH's stock plummeted 22% following CMS's proposed Medicare payment updates for 2027, indicating minimal growth for Medicare Advantage. The company's reliance on Medicare shines a spotlight on its revenue structure, but some analysts view the current price drop as a potential buying opportunity given long-term growth prospects in delegated care agreements.

• ASTH shares fell 22% to $21.48 after CMS proposed modest Medicare payment updates.
• CMS forecasts a mere 0.09% increase in average Medicare Advantage payments for 2027.
• Medicare constitutes about 61% of ASTH's revenue, critical for its performance.
• Analysts suggest current price offers an attractive entry point despite recent decline.
• Potential long-term benefits from CMS changes could enhance ASTH's contract agreements.